Lyell Immunopharma holds 2024 annual meeting; all proposals approved

Lyell Immunopharma, Inc.

Elected Elizabeth Nabel (147.8M for, 16.2M withheld) and Lynn Seely (150.1M for, 13.9M withheld) as Class III directors.
Ratified Ernst & Young as auditor for FY2024 with 198.6M votes for, 153.7K against, 57K abstentions.
Advisory say-on-pay approved: 108.8M for, 47.0M against, 8.2M abstentions; broker non-votes 34.8M.
Quorum of 77.98% (198.8M shares) represented at the June 14, 2024 virtual meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.